Search

The article "Body Fatness Increases Risk of Monoclonal Gammopathy of Undetermined Significance in the U.S. Population" explores the association between obesity markers and the risk of developing MGUS in the U.S. population. Using data from national surveys, the study found that a 1% increase in body fat percentage is linked to a higher risk of MGUS and non-IgM MGUS. However, other obesity markers like BMI, waist circumference, and fat-free mass did not show a significant association with MGUS. The study suggests that while obesity is connected to an increased risk of MGUS, commonly used markers like BMI may not fully capture this relationship. [Extracted from the article]

A recent study from the University of Wisconsin in Madison, United States, focused on Monoclonal Gammopathy of Undetermined Significance (MGUS) and its progression to multiple myeloma. The research highlighted the prevalence of clonal plasma cell disorders and the risk factors associated with MGUS and smoldering multiple myeloma (SMM). The study emphasized the evolving guidelines for diagnosis and treatment of these precursor conditions, signaling a shift in the management of plasma cell disorders. [Extracted from the article]

Researchers at Universidade de Sao Paulo (USP) have published a report on a case of primary amyloidosis with multi-organ involvement in a female patient in her 50s. The patient had a history of relapsing polychondritis, chronic kidney disease, and monoclonal gammopathy of undetermined significance (MGUS). The clinical manifestations included neuropathic pain, liver injury, gastrointestinal symptoms, and myocardial thickening. The patient's condition worsened, leading to her death. The study emphasizes the importance of precise identification in guiding appropriate therapeutic strategies for complex diseases like amyloidosis. [Extracted from the article]

A clinical trial, NCT06472830, has been launched to screen for monoclonal gammopathies in people of East African descent. Monoclonal gammopathy is a condition where abnormal proteins are found in the blood, known as monoclonal gammopathy of undetermined significance (MGUS). This study aims to determine the prevalence of MGUS in this population in order to improve treatment and prevention strategies. The trial involves medical chart review, blood sample collection, and completion of a questionnaire by participants. [Extracted from the article]

A recent study conducted in Istanbul, Turkey, aimed to determine the prevalence of sarcopenia (muscle loss) in patients with monoclonal gammopathy of undetermined significance (MGUS) and evaluate the links between MGUS and sarcopenia. The study found that sarcopenia was present in 34.15% of MGUS patients, with a higher prevalence in males. Factors such as age, low muscle function scores, and low serum free light-chain Lambda levels were associated with sarcopenia in MGUS patients. The researchers suggest that further studies are needed to explore the potential role of sarcopenia in the development of MGUS. [Extracted from the article]

A new report discusses research findings on monoclonal gammopathy of undetermined significance (MGUS) from the Norwegian University of Science and Technology (NTNU). The researchers highlight the lack of reliable biomarkers for guiding treatment decisions and determining suitable therapies for relapse. They conducted proteomic analysis on plasma cells from individuals with MGUS and multiple myeloma (MM) and identified differentially expressed proteins between the two conditions. The study suggests that MM cells activate pathways to ensure translational fidelity and avoid proteotoxic stress, while also reducing the expression of immunoglobulins and surface antigens. The researchers identified potential biomarkers with prognostic and therapeutic value that require further evaluation. [Extracted from the article]

A recent study conducted in Iceland examined the association between autoimmune diseases and monoclonal gammopathy of undetermined significance (MGUS), a precursor to multiple myeloma. The study, which was based on a systematically screened population, found that there was no significant association between autoimmune diseases and MGUS. However, autoimmune disease diagnoses were associated with a prior clinical diagnosis of MGUS. The findings suggest that routine screening for MGUS in patients with autoimmune diseases may not be necessary. [Extracted from the article]

Researchers from the University of Iceland have developed a multivariable prediction model to determine the need for bone marrow sampling in individuals with monoclonal gammopathy of undetermined significance (MGUS). MGUS and smoldering multiple myeloma (SMM) are precursor conditions to multiple myeloma and related disorders. The model accurately predicts the probability of having 10% or greater bone marrow plasma cells, which indicates a higher risk for progression and the need for specialist management. This model may help defer unnecessary bone marrow sampling and referral to hematology. [Extracted from the article]

A clinical trial, NCT06286215, has been launched to register patients with plasma cell disorders. The trial aims to answer questions about the incidence of plasma cell disorders, the progression of monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM) to light chain amyloidosis or multiple myeloma (MM), and factors influencing overall survival and progression-free survival. It also seeks to understand the symptoms and signs of the disease, genetic characteristics, and cost-effectiveness of treatment in Thailand. The trial will collect data from hospital medical records and is set to begin on April 1, 2024, with an estimated completion date of April 1, 2035. [Extracted from the article]

Researchers at Hokkaido University Hospital in Japan have reported findings on a case of type 1 cryoglobulinemic vasculitis associated with monoclonal gammopathy of undetermined significance (MGUS). Cryoglobulins are immunoglobulins that precipitate in cold conditions, and type 1 cryoglobulinemic vasculitis is linked to hematological malignancies. The study found that the main component of cryoglobulin in this case was the M protein due to MGUS, and treatment with bortezomib and dexamethasone resulted in a decrease in cryoglobulin levels and improvement in symptoms. The research suggests that treatment of the underlying gammaglobulinopathy should be considered in refractory cases of type 1 cryoglobulinemic vasculitis. [Extracted from the article]

Researchers at the University of Texas MD Anderson Cancer Center have made new findings in monoclonal gammopathy of undetermined significance (MGUS), a condition associated with multiple myeloma. The researchers found that the incidence of secondary MGUS is limited in patients with multiple myeloma who have undergone chimeric antigen receptor T-cell therapy. They presented a case of secondary MGUS with isotype switching in a multiple myeloma patient, suggesting that this phenomenon may represent pseudo-disease progression and potentially be associated with better outcomes. However, more research is needed to confirm this association. [Extracted from the article]

A recent study conducted by researchers from the University of Toyama in Japan has identified monoclonal gammopathy of undetermined significance (MGUS) as a pre-disease state of multiple myeloma (MM). The researchers used Raman spectroscopy and the dynamical network biomarker (DNB) theory to analyze Raman spectra from patients at different stages of the disease. They found that MGUS is an unstable pre-disease state of MM and identified specific Raman shifts as DNB variables. The study suggests that Raman spectroscopy and DNB analysis could be used to identify pre-disease states in clinical samples. [Extracted from the article]

A recent report from researchers at the Cleveland Clinic in Ohio provides new insights into the clinical and pathological features of IgM monoclonal gammopathy of undetermined significance (MGUS) and its association with IgM-related disorders (IgM-RD). The study found that a subset of patients with IgM MGUS develop IgM-RD, including peripheral neuropathy, cryoglobulinemia, and cold agglutinin disease. The researchers also identified distinctive features in cases of cold agglutinin disease, supporting the concept of it as a distinct clinicopathologic disorder. Overall, the study highlights the common occurrence of IgM-RD in patients with IgM MGUS and provides important information for understanding these conditions. [Extracted from the article]

A recent report from the St. Louis Veterans Affairs Medical Center discusses research on the association between Agent Orange exposure and the progression of monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM) in Vietnam War Era Veterans. The study found that high exposure to Agent Orange was associated with an increased progression rate to MM compared to Veterans with no exposure. The findings are important for informing the risk of progression in patients with MGUS and prior Agent Orange exposure, as well as those with occupational exposure to herbicides and pesticides. [Extracted from the article]

A recent study from Johns Hopkins University School of Medicine explores the surgical management of a patient with ocular copper deposition associated with monoclonal gammopathy of undetermined significance (MGUS). The case report focuses on a 44-year-old man with MGUS who presented with bilateral diffuse deposition of copper in the cornea and lens. Despite systemic therapy for MGUS, corneal clearing was not observed, leading to cataract extraction and other advanced surgical techniques to improve vision. The study concludes that ocular copper deposition is a rare manifestation of MGUS and that cataract extraction can be challenging, requiring advanced techniques such as endoillumination to improve visualization. [Extracted from the article]

A study conducted by researchers at the National and Kapodistrian University of Athens explores the relationship between monoclonal gammopathy of undetermined significance (MGUS) and cardiovascular disease. MGUS is a premalignant condition characterized by low levels of a monoclonal protein in the blood and a low percentage of clonal plasma cells in the bone marrow. The study suggests that MGUS may have adverse effects on the cardiovascular system, and patients with MGUS may benefit from regular cardiovascular risk assessment to prevent severe cardiovascular complications. The mechanisms underlying this association are not fully understood but may involve genetic abnormalities, vascular calcification, cryoglobulinemia, cold agglutinin disease, autoantibodies, and the direct or indirect effects of the monoclonal protein on the vascular endothelium. [Extracted from the article]

A recent study conducted by the University of Iceland has found that next-generation flow cytometry (NGF) can be used to predict the presence of an underlying clonal plasma cell population in individuals with light-chain monoclonal gammopathy of undetermined significance (LC-MGUS). The study included 1,965 individuals with LC disease and found that clonal plasma cells were identified in 38.1% of LC-MGUS cases. The study also determined that an involved/uninvolved free light-chain (FLC) ratio cutoff of 3.15 was highly predictive of clonal plasma cell presence and that individuals with an FLC ratio below this cutoff did not experience disease progression during follow-up. These findings suggest that NGF and the FLC ratio cutoff can assist in managing LC-MGUS. [Extracted from the article]

A study conducted by researchers at the University of Texas MD Anderson Cancer Center examined the cytogenetic profiles of plasma cell neoplasms (PCNs) at different disease stages, including monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), newly diagnosed multiple myeloma (NDMM), and refractory/relapsed multiple myeloma (RRMM). The study found that 96% of patients exhibited at least one cytogenetic abnormality, with the genomic complexity increasing as the disease progressed. High-risk cytogenetics, such as 1q gain and del(17p), were more prevalent in RRMM cases. Chromosome 1 structural abnormalities were the most common, found in 65% of cases. The study highlights the genomic heterogeneity and instability in this patient cohort. [Extracted from the article]

A recent study conducted by researchers at Boston University explores the prevalence and risk factors associated with monoclonal gammopathy of undetermined significance (MGUS), a pre-malignant plasma cell disorder. The study found that the prevalence of MGUS varied from 0.24% to 9% across different geographic locations. Modifiable risk factors for MGUS include infections, autoimmune diseases, chronic inflammatory conditions, lifestyle factors, environmental exposures, and ionizing radiation. The researchers suggest that further studies are needed to better understand the genetic and environmental interactions that contribute to MGUS and to develop effective screening and prevention strategies. [Extracted from the article]

Controlling nutritional status index (CONUT), prognostic nutritional index (PNI), geriatric nutritional risk index (GNRI) and body mass index (BMI) were calculated as indices of nutritional status of the participants. Keywords: Blood Protein Disorders; Diet and Nutrition; Health and Medicine; Hematologic Diseases and Conditions; Hemic and Lymphatic Diseases and Conditions; Hypergammaglobulinemia; Monoclonal Gammopathy of Undetermined Significance; Paraproteinemias; Risk and Prevention EN Blood Protein Disorders Diet and Nutrition Health and Medicine Hematologic Diseases and Conditions Hemic and Lymphatic Diseases and Conditions Hypergammaglobulinemia Monoclonal Gammopathy of Undetermined Significance Paraproteinemias Risk and Prevention 533 533 1 10/16/23 20231017 NES 231017 2023 OCT 16 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Researchers detail new data in monoclonal gammopathy of undetermined significance. [Extracted from the article]

Keywords: Boston; State:Massachusetts; United States; North and Central America; Blood Protein Disorders; Diet and Nutrition; Health and Medicine; Hematologic Diseases and Conditions; Hemic and Lymphatic Diseases and Conditions; Hypergammaglobulinemia; Monoclonal Gammopathy of Undetermined Significance; Paraproteinemias; Risk and Prevention; Vitamin D; Vitamins EN Boston State:Massachusetts United States North and Central America Blood Protein Disorders Diet and Nutrition Health and Medicine Hematologic Diseases and Conditions Hemic and Lymphatic Diseases and Conditions Hypergammaglobulinemia Monoclonal Gammopathy of Undetermined Significance Paraproteinemias Risk and Prevention Vitamin D Vitamins 1738 1738 1 10/16/23 20231017 NES 231017 2023 OCT 16 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Current study results on Hematologic Diseases and Conditions - Monoclonal Gammopathy of Undetermined Significance have been published. Keywords for this news article include: Boston, Massachusetts, United States, North and Central America, Blood Protein Disorders, Diet and Nutrition, Health and Medicine, Hematologic Diseases and Conditions, Hemic and Lymphatic Diseases and Conditions, Hypergammaglobulinemia, Monoclonal Gammopathy of Undetermined Significance, Paraproteinemias, Risk and Prevention, Vitamin D, Vitamins, Boston University. [Extracted from the article]

Keywords: Blood Protein Disorders; Brain Diseases and Conditions; Enzymes and Coenzymes; Gaucher Disease; Gaucher's Disease; Genetics; Glucosidases; Health and Medicine; Hematologic Diseases and Conditions; Hematology; Hemic and Lymphatic Diseases and Conditions; Hypergammaglobulinemia; Lipid Metabolism Disorders; Lysosomal Storage Diseases and Conditions; Metabolic Diseases and Conditions; Monoclonal Gammopathy of Undetermined Significance; Nutritional and Metabolic Diseases and Conditions; Paraproteinemias; Sphingolipidoses EN Blood Protein Disorders Brain Diseases and Conditions Enzymes and Coenzymes Gaucher Disease Gaucher's Disease Genetics Glucosidases Health and Medicine Hematologic Diseases and Conditions Hematology Hemic and Lymphatic Diseases and Conditions Hypergammaglobulinemia Lipid Metabolism Disorders Lysosomal Storage Diseases and Conditions Metabolic Diseases and Conditions Monoclonal Gammopathy of Undetermined Significance Nutritional and Metabolic Diseases and Conditions Paraproteinemias Sphingolipidoses 949 949 1 10/09/23 20231012 NES 231012 2023 OCT 13 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Investigators discuss new findings in monoclonal gammopathy of undetermined significance. Blood Protein Disorders, Brain Diseases and Conditions, Enzymes and Coenzymes, Gaucher Disease, Gaucher's Disease, Genetics, Glucosidases, Health and Medicine, Hematologic Diseases and Conditions, Hematology, Hemic and Lymphatic Diseases and Conditions, Hypergammaglobulinemia, Lipid Metabolism Disorders, Lysosomal Storage Diseases and Conditions, Metabolic Diseases and Conditions, Nutritional and Metabolic Diseases and Conditions, Paraproteinemias, Sphingolipidoses, Monoclonal Gammopathy of Undetermined Significance. [Extracted from the article]

Keywords: Bariatrics; Blood Protein Disorders; Cancer; Diet and Nutrition; Epidemiology; Health and Medicine; Hematologic Diseases and Conditions; Hematology; Hemic and Lymphatic Diseases and Conditions; Hemorrhagic Disorders; Hemostatic Disorders; Hypergammaglobulinemia; Immunoproliferative Disorders; Lymphoproliferative Disorders; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Myeloma; Nutrition Disorders; Nutritional and Metabolic Diseases and Conditions; Obesity; Obesity and Diabetes; Oncology; Overnutrition; Paraproteinemias; Risk and Prevention; Vascular Diseases and Conditions EN Bariatrics Blood Protein Disorders Cancer Diet and Nutrition Epidemiology Health and Medicine Hematologic Diseases and Conditions Hematology Hemic and Lymphatic Diseases and Conditions Hemorrhagic Disorders Hemostatic Disorders Hypergammaglobulinemia Immunoproliferative Disorders Lymphoproliferative Disorders Monoclonal Gammopathy of Undetermined Significance Multiple Myeloma Myeloma Nutrition Disorders Nutritional and Metabolic Diseases and Conditions Obesity Obesity and Diabetes Oncology Overnutrition Paraproteinemias Risk and Prevention Vascular Diseases and Conditions 425 425 1 10/03/23 20231003 NES 231003 2023 OCT 2 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- New research on monoclonal gammopathy of undetermined significance is the subject of a new report. [Extracted from the article]

Keywords: Sarasota; State:Florida; United States; North and Central America; Blood Protein Disorders; Disease Attributes; Disease Progression; Health and Medicine; Hematologic Diseases and Conditions; Hemic and Lymphatic Diseases and Conditions; Hypergammaglobulinemia; Immune System Diseases and Conditions; Immunoproliferative Disorders; Monoclonal Gammopathy of Undetermined Significance; Paraproteinemias; Risk and Prevention EN Sarasota State:Florida United States North and Central America Blood Protein Disorders Disease Attributes Disease Progression Health and Medicine Hematologic Diseases and Conditions Hemic and Lymphatic Diseases and Conditions Hypergammaglobulinemia Immune System Diseases and Conditions Immunoproliferative Disorders Monoclonal Gammopathy of Undetermined Significance Paraproteinemias Risk and Prevention 1277 1277 1 09/04/23 20230904 NES 230904 2023 SEP 8 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Researchers detail new data in Hematologic Diseases and Conditions - Monoclonal Gammopathy of Undetermined Significance. Sarasota, State:Florida, United States, North and Central America, Blood Protein Disorders, Disease Attributes, Disease Progression, Health and Medicine, Hematologic Diseases and Conditions, Hemic and Lymphatic Diseases and Conditions, Hypergammaglobulinemia, Immune System Diseases and Conditions, Immunoproliferative Disorders, Monoclonal Gammopathy of Undetermined Significance, Paraproteinemias, Risk and Prevention. [Extracted from the article]

For more information on this research see: Acquired Von Willebrand Syndrome In Patients With Monoclonal Gammopathy of Undetermined Significance Investigated Using a Mechanistic Approach. Keywords: Padua; Italy; Europe; Blood Protein Disorders; Health and Medicine; Hematologic Diseases and Conditions; Hemic and Lymphatic Diseases and Conditions; Hypergammaglobulinemia; Mathematics; Monoclonal Gammopathy of Undetermined Significance; Paraproteinemias; Von Willebrand Disease EN Padua Italy Europe Blood Protein Disorders Health and Medicine Hematologic Diseases and Conditions Hemic and Lymphatic Diseases and Conditions Hypergammaglobulinemia Mathematics Monoclonal Gammopathy of Undetermined Significance Paraproteinemias Von Willebrand Disease 237 237 1 08/21/23 20230821 NES 230821 2023 AUG 21 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Investigators discuss new findings in Hematologic Diseases and Conditions - Monoclonal Gammopathy of Undetermined Significance. [Extracted from the article]

Atrial Fibrillation, Blood Protein Disorders, Cardiac Arrhythmias, Cardiovascular Diseases and Conditions, Health and Medicine, Heart Disease, Heart Disorders and Diseases, Hematologic Diseases and Conditions, Hemic and Lymphatic Diseases and Conditions, Hospitals, Hypergammaglobulinemia, Monoclonal Gammopathy of Undetermined Significance, Paraproteinemias, Risk and Prevention Keywords: Atrial Fibrillation; Blood Protein Disorders; Cardiac Arrhythmias; Cardiovascular Diseases and Conditions; Health and Medicine; Heart Disease; Heart Disorders and Diseases; Hematologic Diseases and Conditions; Hemic and Lymphatic Diseases and Conditions; Hospitals; Hypergammaglobulinemia; Monoclonal Gammopathy of Undetermined Significance; Paraproteinemias; Risk and Prevention EN Atrial Fibrillation Blood Protein Disorders Cardiac Arrhythmias Cardiovascular Diseases and Conditions Health and Medicine Heart Disease Heart Disorders and Diseases Hematologic Diseases and Conditions Hemic and Lymphatic Diseases and Conditions Hospitals Hypergammaglobulinemia Monoclonal Gammopathy of Undetermined Significance Paraproteinemias Risk and Prevention 618 618 1 07/24/23 20230728 NES 230728 2023 JUL 24 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- A new study on monoclonal gammopathy of undetermined significance is now available. [Extracted from the article]

Keywords: Blood Protein Disorders; Bone Marrow; Bone Research; Cancer; Drugs and Therapies; Genetics; Health and Medicine; Hematologic Diseases and Conditions; Hematology; Hemic and Lymphatic Diseases and Conditions; Hemorrhagic Disorders; Hemostatic Disorders; Hypergammaglobulinemia; Immunoproliferative Disorders; Lymphoproliferative Disorders; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Myeloma; Oncology; Paraproteinemias; Pharmaceuticals; Risk and Prevention; Vascular Diseases and Conditions EN Blood Protein Disorders Bone Marrow Bone Research Cancer Drugs and Therapies Genetics Health and Medicine Hematologic Diseases and Conditions Hematology Hemic and Lymphatic Diseases and Conditions Hemorrhagic Disorders Hemostatic Disorders Hypergammaglobulinemia Immunoproliferative Disorders Lymphoproliferative Disorders Monoclonal Gammopathy of Undetermined Significance Multiple Myeloma Myeloma Oncology Paraproteinemias Pharmaceuticals Risk and Prevention Vascular Diseases and Conditions 370 370 1 07/17/23 20230717 NES 230717 2023 JUL 20 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- New research on monoclonal gammopathy of undetermined significance is the subject of a new report. Blood Protein Disorders, Bone Marrow, Bone Research, Cancer, Drugs and Therapies, Genetics, Health and Medicine, Hematologic Diseases and Conditions, Hematology, Hemic and Lymphatic Diseases and Conditions, Hemorrhagic Disorders, Hemostatic Disorders, Hypergammaglobulinemia, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Myeloma, Oncology, Paraproteinemias, Pharmaceuticals, Risk and Prevention, Vascular Diseases and Conditions, Monoclonal Gammopathy of Undetermined Significance. [Extracted from the article]

Sometimes atypical banding patterns are seen in serum capillary electrophoresis that pose diagnostic dilemmas and may require repeat testing and further confirmation with a diagnostic test. Keywords: Blood Protein Disorders; Capillary Electrophoresis; Chromatography; Diagnostics and Screening; Health and Medicine; Hematologic Diseases and Conditions; Hemic and Lymphatic Diseases and Conditions; Hypergammaglobulinemia; Monoclonal Gammopathy of Undetermined Significance; Paraproteinemias EN Blood Protein Disorders Capillary Electrophoresis Chromatography Diagnostics and Screening Health and Medicine Hematologic Diseases and Conditions Hemic and Lymphatic Diseases and Conditions Hypergammaglobulinemia Monoclonal Gammopathy of Undetermined Significance Paraproteinemias 153 153 1 06/19/23 20230620 NES 230620 2023 JUN 19 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Current study results on monoclonal gammopathy of undetermined significance have been published. [Extracted from the article]

Ningbo, People's Republic of China, Asia, Anemia, Antiphospholipid Syndrome, Autoimmune Diseases and Conditions, Beta Thalassemia, Blood Protein Disorders, Congenital Anemia, Health and Medicine, Hematologic Diseases and Conditions, Hematology, Hemic and Lymphatic Diseases and Conditions, Hemoglobinopathies, Hemolytic, Hypergammaglobulinemia, Immune System Diseases and Conditions, Mental Health Diseases and Conditions, Monoclonal Gammopathy of Undetermined Significance, Paraproteinemias, Psychiatry, Schizophrenia, Thalassemia Keywords for this news article include: Ningbo, People's Republic of China, Asia, Anemia, Antiphospholipid Syndrome, Autoimmune Diseases and Conditions, Beta Thalassemia, Blood Protein Disorders, Congenital Anemia, Health and Medicine, Hematologic Diseases and Conditions, Hematology, Hemic and Lymphatic Diseases and Conditions, Hemoglobinopathies, Hemolytic, Hypergammaglobulinemia, Immune System Diseases and Conditions, Mental Health Diseases and Conditions, Monoclonal Gammopathy of Undetermined Significance, Paraproteinemias, Psychiatry, Schizophrenia, Thalassemia, Department of Hematology and Oncology. [Extracted from the article]

Keywords: Boston; State:Massachusetts; United States; North and Central America; Biomarkers; Blood Protein Disorders; Bone Marrow; Bone Research; Cancer; Diagnostics and Screening; Health and Medicine; Hematologic Diseases and Conditions; Hematology; Hemic and Lymphatic Diseases and Conditions; Hemorrhagic Disorders; Hemostatic Disorders; Hypergammaglobulinemia; Immunoproliferative Disorders; Lymphoproliferative Disorders; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Myeloma; Oncology; Paraproteinemias; Risk and Prevention; Vascular Diseases and Conditions EN Boston State:Massachusetts United States North and Central America Biomarkers Blood Protein Disorders Bone Marrow Bone Research Cancer Diagnostics and Screening Health and Medicine Hematologic Diseases and Conditions Hematology Hemic and Lymphatic Diseases and Conditions Hemorrhagic Disorders Hemostatic Disorders Hypergammaglobulinemia Immunoproliferative Disorders Lymphoproliferative Disorders Monoclonal Gammopathy of Undetermined Significance Multiple Myeloma Myeloma Oncology Paraproteinemias Risk and Prevention Vascular Diseases and Conditions 258 258 1 04/24/23 20230425 NES 230425 2023 APR 24 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Investigators discuss new findings in Hematologic Diseases and Conditions - Monoclonal Gammopathy of Undetermined Significance. We compared the PANGEA models (with bone marrow [BM] data and without bone marrow [no BM] data) to current criteria (International Myeloma Working Group [IMWG] monoclonal gammopathy of undetermined significance and 20/2/20 smouldering multiple myeloma risk criteria). [Extracted from the article]

Keywords for this news article include: Ningbo No.2 Hospital, Ningbo, People's Republic of China, Asia, Antiphospholipid Syndrome, Hemolytic, Psychiatry, Thalassemia, Schizophrenia, Paraproteinemias, Congenital Anemia, Hemoglobinopathies, Health and Medicine, Hypergammaglobulinemia, Blood Protein Disorders, Autoimmune Diseases and Conditions, Hematologic Diseases and Conditions, Immune System Diseases and Conditions. Antiphospholipid Syndrome, Autoimmune Diseases and Conditions, Blood Protein Disorders, Congenital Anemia, Health and Medicine, Hematologic Diseases and Conditions, Hematology, Hemic and Lymphatic Diseases and Conditions, Hemoglobinopathies, Hemolytic, Hypergammaglobulinemia, Immune System Diseases and Conditions, Mental Health Diseases and Conditions, Monoclonal Gammopathy of Undetermined Significance, Paraproteinemias, Psychiatry, Schizophrenia, Thalassemia. [Extracted from the article]

Keywords: Worcester; State:Massachusetts; United States; North and Central America; Blood Protein Disorders; Cancer; Diagnostics and Screening; Health and Medicine; Hematologic Diseases and Conditions; Hemic and Lymphatic Diseases and Conditions; Hypergammaglobulinemia; Monoclonal Gammopathy of Undetermined Significance; Oncology; Paraproteinemias; Precancerous Conditions EN Worcester State:Massachusetts United States North and Central America Blood Protein Disorders Cancer Diagnostics and Screening Health and Medicine Hematologic Diseases and Conditions Hemic and Lymphatic Diseases and Conditions Hypergammaglobulinemia Monoclonal Gammopathy of Undetermined Significance Oncology Paraproteinemias Precancerous Conditions 1281 1281 1 04/10/23 20230413 NES 230413 2023 APR 11 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Researchers detail new data in Hematologic Diseases and Conditions - Monoclonal Gammopathy of Undetermined Significance. For more information on this research see: Patient and Provider-level Drivers of Healthcare Utilization Related To a Diagnosis of a Precancerous Condition: Monoclonal Gammopathy of Undetermined Significance (Mgus). [Extracted from the article]

Antineoplastics, Blood Protein Disorders, Blood Proteins, Cryoglobulinemia, Cryoglobulins, Diagnostics and Screening, Health and Medicine, Hematologic Diseases and Conditions, Hemic and Lymphatic Diseases and Conditions, Hemorrhagic Disorders, Hemostatic Disorders, Hypergammaglobulinemia, Immunoglobulin Isotypes, Immunoglobulin M, Immunoglobulins, Immunology, Immunoproliferative Disorders, Immunoproteins, Monoclonal Gammopathy of Undetermined Significance, Paraproteinemias, Proteins, Serum Globulins, Vascular Diseases and Conditions, Paraproteins For more information on this research see: Beyond monoclonal gammopathy of undetermined significance, clinical spectrum of immunoglobulin M gammopathy: a case series with focus on the diagnostic and management challenges. [Extracted from the article]

The inhibition of the pathogenic effects of the IgM has led to great success in cold agglutinin disease and Schnitzler syndrome, whereas the other treatments are centered on eradicating the underlying clone. Keywords: Amsterdam; Netherlands; Europe; Diagnostics and Screening; Health and Medicine; Immune System Diseases and Conditions; Immunoproliferative Disorders; Monoclonal Gammopathy of Undetermined Significance; Paraproteinemias; Schnitzler Syndrome EN Amsterdam Netherlands Europe Diagnostics and Screening Health and Medicine Immune System Diseases and Conditions Immunoproliferative Disorders Monoclonal Gammopathy of Undetermined Significance Paraproteinemias Schnitzler Syndrome 2023 MAR 13 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- A new study on Immune System Diseases and Conditions - Schnitzler Syndrome is now available. [Extracted from the article]